NCT06871007View on ClinicalTrials.gov

Nivolumab and DA-EPOCH-R in Pediatric Primary Mediastinal (Thymic) Large B-cell Lymphoma

PHASE1/PHASE2Enrolling by invitationINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

September 1, 2024

Primary Completion Date

September 1, 2029

Study Completion Date

September 1, 2031

Conditions
Primary Mediastinal (Thymic) Large B-cell LymphomaChildrenNivolumab
Interventions
DRUG

Nivolumab

Nivolumab 40 mg on Day 2 is added to dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab; DA-EPOCH-R).Standard guidelines for conducting the DA-EPOCH-R protocol will be used.

Trial Locations (2)

196022

Pavlov University, RM Gorbacheva Research Institute, Saint Petersburg

Unknown

Dmitry Rogachev National Research Center, Moscow

All Listed Sponsors
lead

St. Petersburg State Pavlov Medical University

OTHER